Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience
Background: Treatment of Ewing sarcoma (ES) requires multidisciplinary approach and deficiencies in treatment adversely affect the results. This study included patients diagnosed with ES and aimed to determine the factors affecting prognosis and investigate the efficacy of replacing actinomycin-D wi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-08-01
|
| Series: | Journal of Bone Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137422000252 |
| _version_ | 1798038085419663360 |
|---|---|
| author | Ayşe Özkan İbrahim Bayram Gülay Sezgin Akif Mirioğlu Serhan Küpeli |
| author_facet | Ayşe Özkan İbrahim Bayram Gülay Sezgin Akif Mirioğlu Serhan Küpeli |
| author_sort | Ayşe Özkan |
| collection | DOAJ |
| description | Background: Treatment of Ewing sarcoma (ES) requires multidisciplinary approach and deficiencies in treatment adversely affect the results. This study included patients diagnosed with ES and aimed to determine the factors affecting prognosis and investigate the efficacy of replacing actinomycin-D with carboplatin in consolidation treatment. Methods: Eighty-two pediatric ES patients diagnosed at a single institution between 2005 and 2020 were retrospectively evaluated. Clinical and epidemiological features, treatment modalities, prognostic criteria, and overall survival (OS) rates of patients revieved. In consolidation treatment, 22 patients were treated with actinomycin-D and 32 patients with carboplatin (500 mg/m2/dose), 24 patients could not receive consolidation treatment. The 5- and 10-year OS rates of the patients were compared. Results: The 5- and 10-year OS rates of the 82 patients with ES were 46% and 40%, respectively. The 5-year OS rates in the group with localized disease (n = 55) and metastasis (n = 27) at diagnosis were 54% and 26%, respectively (p = 0.006). When evaluated according to the consolidation treatment administered both the 5- and 10-year OS rates of the patients receiving actinomycin-D were 50%. The 5-year OS rate was 58% in the carboplatin group, and the 5- and 10-year OS rates of patients that did not receive consolidation treatment was 20%. Conclusions: Survival was significantly worse in the group that did not receive consolidation treatment. Furthermore, our results suggested that carboplatin could be used effectively as an alternative to actinomycin-D in ES consolidation treatment. |
| first_indexed | 2024-04-11T21:35:24Z |
| format | Article |
| id | doaj.art-01e4fc3e191e42fbaf6eae940e4f3d68 |
| institution | Directory Open Access Journal |
| issn | 2212-1374 |
| language | English |
| last_indexed | 2024-04-11T21:35:24Z |
| publishDate | 2022-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Bone Oncology |
| spelling | doaj.art-01e4fc3e191e42fbaf6eae940e4f3d682022-12-22T04:01:45ZengElsevierJournal of Bone Oncology2212-13742022-08-0135100435Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experienceAyşe Özkan0İbrahim Bayram1Gülay Sezgin2Akif Mirioğlu3Serhan Küpeli4Cukurova University, Faculty of Medicine, Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Adana, Turkey; Corresponding author.Cukurova University, Faculty of Medicine, Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Adana, TurkeyCukurova University, Faculty of Medicine, Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Adana, TurkeyCukurova University, Faculty of Medicine, Department of Orthopaedics and Traumatology, Adana, TurkeyCukurova University, Faculty of Medicine, Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Adana, TurkeyBackground: Treatment of Ewing sarcoma (ES) requires multidisciplinary approach and deficiencies in treatment adversely affect the results. This study included patients diagnosed with ES and aimed to determine the factors affecting prognosis and investigate the efficacy of replacing actinomycin-D with carboplatin in consolidation treatment. Methods: Eighty-two pediatric ES patients diagnosed at a single institution between 2005 and 2020 were retrospectively evaluated. Clinical and epidemiological features, treatment modalities, prognostic criteria, and overall survival (OS) rates of patients revieved. In consolidation treatment, 22 patients were treated with actinomycin-D and 32 patients with carboplatin (500 mg/m2/dose), 24 patients could not receive consolidation treatment. The 5- and 10-year OS rates of the patients were compared. Results: The 5- and 10-year OS rates of the 82 patients with ES were 46% and 40%, respectively. The 5-year OS rates in the group with localized disease (n = 55) and metastasis (n = 27) at diagnosis were 54% and 26%, respectively (p = 0.006). When evaluated according to the consolidation treatment administered both the 5- and 10-year OS rates of the patients receiving actinomycin-D were 50%. The 5-year OS rate was 58% in the carboplatin group, and the 5- and 10-year OS rates of patients that did not receive consolidation treatment was 20%. Conclusions: Survival was significantly worse in the group that did not receive consolidation treatment. Furthermore, our results suggested that carboplatin could be used effectively as an alternative to actinomycin-D in ES consolidation treatment.http://www.sciencedirect.com/science/article/pii/S2212137422000252Ewing sarcomaActinomycin-DCarboplatin |
| spellingShingle | Ayşe Özkan İbrahim Bayram Gülay Sezgin Akif Mirioğlu Serhan Küpeli Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience Journal of Bone Oncology Ewing sarcoma Actinomycin-D Carboplatin |
| title | Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience |
| title_full | Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience |
| title_fullStr | Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience |
| title_full_unstemmed | Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience |
| title_short | Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience |
| title_sort | efficacy of replacing actinomycin d with carboplatin in ewing sarcoma consolidation treatment single center experience |
| topic | Ewing sarcoma Actinomycin-D Carboplatin |
| url | http://www.sciencedirect.com/science/article/pii/S2212137422000252 |
| work_keys_str_mv | AT ayseozkan efficacyofreplacingactinomycindwithcarboplatininewingsarcomaconsolidationtreatmentsinglecenterexperience AT ibrahimbayram efficacyofreplacingactinomycindwithcarboplatininewingsarcomaconsolidationtreatmentsinglecenterexperience AT gulaysezgin efficacyofreplacingactinomycindwithcarboplatininewingsarcomaconsolidationtreatmentsinglecenterexperience AT akifmirioglu efficacyofreplacingactinomycindwithcarboplatininewingsarcomaconsolidationtreatmentsinglecenterexperience AT serhankupeli efficacyofreplacingactinomycindwithcarboplatininewingsarcomaconsolidationtreatmentsinglecenterexperience |